<billStatus>
 <version>
  3.0.0
 </version>
 <bill>
  <number>
   2148
  </number>
  <updateDate>
   2023-01-11T13:48:04Z
  </updateDate>
  <updateDateIncludingText>
   2023-01-11T13:48:04Z
  </updateDateIncludingText>
  <originChamber>
   House
  </originChamber>
  <type>
   HR
  </type>
  <introducedDate>
   2021-03-23
  </introducedDate>
  <congress>
   117
  </congress>
  <constitutionalAuthorityStatementText>
   &lt;pre&gt;[Congressional Record Volume 167, Number 54 (Tuesday, March 23, 2021)][House]From the Congressional Record Online through the Government Publishing Office [&lt;a href="https://www.gpo.gov"&gt;www.gpo.gov&lt;/a&gt;]By Mr. KHANNA:H.R. 2148.Congress has the power to enact this legislation pursuantto the following:Article I, Section 8[Page H1622]&lt;/pre&gt;
  </constitutionalAuthorityStatementText>
  <committees>
   <item>
    <systemCode>
     hsju00
    </systemCode>
    <name>
     Judiciary Committee
    </name>
    <chamber>
     House
    </chamber>
    <type>
     Standing
    </type>
    <subcommittees>
     <item>
      <systemCode>
       hsju05
      </systemCode>
      <name>
       Administrative State, Regulatory Reform, and Antitrust Subcommittee
      </name>
      <activities>
       <item>
        <name>
         Referred to
        </name>
        <date>
         2021-10-19T20:23:41Z
        </date>
       </item>
      </activities>
     </item>
    </subcommittees>
    <activities>
     <item>
      <name>
       Referred to
      </name>
      <date>
       2021-03-23T15:02:45Z
      </date>
     </item>
    </activities>
   </item>
   <item>
    <systemCode>
     hsif00
    </systemCode>
    <name>
     Energy and Commerce Committee
    </name>
    <chamber>
     House
    </chamber>
    <type>
     Standing
    </type>
    <subcommittees>
     <item>
      <systemCode>
       hsif14
      </systemCode>
      <name>
       Health Subcommittee
      </name>
      <activities>
       <item>
        <name>
         Referred to
        </name>
        <date>
         2021-03-24T15:23:15Z
        </date>
       </item>
      </activities>
     </item>
    </subcommittees>
    <activities>
     <item>
      <name>
       Referred to
      </name>
      <date>
       2021-03-23T15:02:40Z
      </date>
     </item>
    </activities>
   </item>
  </committees>
  <relatedBills>
   <item>
    <title>
     Prescription Drug Price Relief Act of 2021
    </title>
    <congress>
     117
    </congress>
    <number>
     909
    </number>
    <type>
     S
    </type>
    <latestAction>
     <actionDate>
      2021-03-23
     </actionDate>
     <text>
      Committee on Health, Education, Labor, and Pensions Subcommittee on Primary Health and Retirement Security. Hearings held.
     </text>
    </latestAction>
    <relationshipDetails>
     <item>
      <type>
       Identical bill
      </type>
      <identifiedBy>
       CRS
      </identifiedBy>
     </item>
    </relationshipDetails>
   </item>
  </relatedBills>
  <actions>
   <item>
    <actionDate>
     2021-10-19
    </actionDate>
    <committees>
     <item>
      <systemCode>
       hsju05
      </systemCode>
      <name>
       Administrative State, Regulatory Reform, and Antitrust Subcommittee
      </name>
     </item>
    </committees>
    <sourceSystem>
     <code>
      1
     </code>
     <name>
      House committee actions
     </name>
    </sourceSystem>
    <text>
     Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
    </text>
    <type>
     Committee
    </type>
   </item>
   <item>
    <actionDate>
     2021-03-24
    </actionDate>
    <committees>
     <item>
      <systemCode>
       hsif14
      </systemCode>
      <name>
       Health Subcommittee
      </name>
     </item>
    </committees>
    <sourceSystem>
     <code>
      1
     </code>
     <name>
      House committee actions
     </name>
    </sourceSystem>
    <text>
     Referred to the Subcommittee on Health.
    </text>
    <type>
     Committee
    </type>
   </item>
   <item>
    <actionDate>
     2021-03-23
    </actionDate>
    <text>
     Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
    </text>
    <type>
     IntroReferral
    </type>
    <actionCode>
     H11100
    </actionCode>
    <sourceSystem>
     <code>
      2
     </code>
     <name>
      House floor actions
     </name>
    </sourceSystem>
    <committees>
     <item>
      <systemCode>
       hsju00
      </systemCode>
      <name>
       Judiciary Committee
      </name>
     </item>
    </committees>
   </item>
   <item>
    <actionDate>
     2021-03-23
    </actionDate>
    <text>
     Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
    </text>
    <type>
     IntroReferral
    </type>
    <actionCode>
     H11100
    </actionCode>
    <sourceSystem>
     <code>
      2
     </code>
     <name>
      House floor actions
     </name>
    </sourceSystem>
    <committees>
     <item>
      <systemCode>
       hsif00
      </systemCode>
      <name>
       Energy and Commerce Committee
      </name>
     </item>
    </committees>
   </item>
   <item>
    <actionDate>
     2021-03-23
    </actionDate>
    <text>
     Introduced in House
    </text>
    <type>
     IntroReferral
    </type>
    <actionCode>
     Intro-H
    </actionCode>
    <sourceSystem>
     <code>
      9
     </code>
     <name>
      Library of Congress
     </name>
    </sourceSystem>
   </item>
   <item>
    <actionDate>
     2021-03-23
    </actionDate>
    <text>
     Introduced in House
    </text>
    <type>
     IntroReferral
    </type>
    <actionCode>
     1000
    </actionCode>
    <sourceSystem>
     <code>
      9
     </code>
     <name>
      Library of Congress
     </name>
    </sourceSystem>
   </item>
  </actions>
  <sponsors>
   <item>
    <bioguideId>
     K000389
    </bioguideId>
    <fullName>
     Rep. Khanna, Ro [D-CA-17]
    </fullName>
    <firstName>
     Ro
    </firstName>
    <lastName>
     Khanna
    </lastName>
    <party>
     D
    </party>
    <state>
     CA
    </state>
    <district>
     17
    </district>
    <isByRequest>
     N
    </isByRequest>
   </item>
  </sponsors>
  <cosponsors>
   <item>
    <bioguideId>
     B001223
    </bioguideId>
    <fullName>
     Rep. Bowman, Jamaal [D-NY-16]
    </fullName>
    <firstName>
     Jamaal
    </firstName>
    <lastName>
     Bowman
    </lastName>
    <party>
     D
    </party>
    <state>
     NY
    </state>
    <district>
     16
    </district>
    <sponsorshipDate>
     2021-03-23
    </sponsorshipDate>
    <isOriginalCosponsor>
     True
    </isOriginalCosponsor>
   </item>
   <item>
    <bioguideId>
     D000191
    </bioguideId>
    <fullName>
     Rep. DeFazio, Peter A. [D-OR-4]
    </fullName>
    <firstName>
     PETER
    </firstName>
    <lastName>
     DEFAZIO
    </lastName>
    <party>
     D
    </party>
    <state>
     OR
    </state>
    <middleName>
     A.
    </middleName>
    <district>
     4
    </district>
    <sponsorshipDate>
     2021-03-23
    </sponsorshipDate>
    <isOriginalCosponsor>
     True
    </isOriginalCosponsor>
   </item>
   <item>
    <bioguideId>
     D000216
    </bioguideId>
    <fullName>
     Rep. DeLauro, Rosa L. [D-CT-3]
    </fullName>
    <firstName>
     ROSA
    </firstName>
    <lastName>
     DELAURO
    </lastName>
    <party>
     D
    </party>
    <state>
     CT
    </state>
    <district>
     3
    </district>
    <sponsorshipDate>
     2021-03-23
    </sponsorshipDate>
    <isOriginalCosponsor>
     True
    </isOriginalCosponsor>
   </item>
   <item>
    <bioguideId>
     J000298
    </bioguideId>
    <fullName>
     Rep. Jayapal, Pramila [D-WA-7]
    </fullName>
    <firstName>
     Pramila
    </firstName>
    <lastName>
     Jayapal
    </lastName>
    <party>
     D
    </party>
    <state>
     WA
    </state>
    <district>
     7
    </district>
    <sponsorshipDate>
     2021-03-23
    </sponsorshipDate>
    <isOriginalCosponsor>
     True
    </isOriginalCosponsor>
   </item>
   <item>
    <bioguideId>
     J000306
    </bioguideId>
    <fullName>
     Rep. Jones, Mondaire [D-NY-17]
    </fullName>
    <firstName>
     Mondaire
    </firstName>
    <lastName>
     Jones
    </lastName>
    <party>
     D
    </party>
    <state>
     NY
    </state>
    <district>
     17
    </district>
    <sponsorshipDate>
     2021-03-23
    </sponsorshipDate>
    <isOriginalCosponsor>
     True
    </isOriginalCosponsor>
   </item>
   <item>
    <bioguideId>
     L000551
    </bioguideId>
    <fullName>
     Rep. Lee, Barbara [D-CA-13]
    </fullName>
    <firstName>
     BARBARA
    </firstName>
    <lastName>
     LEE
    </lastName>
    <party>
     D
    </party>
    <state>
     CA
    </state>
    <district>
     13
    </district>
    <sponsorshipDate>
     2021-03-23
    </sponsorshipDate>
    <isOriginalCosponsor>
     True
    </isOriginalCosponsor>
   </item>
   <item>
    <bioguideId>
     N000191
    </bioguideId>
    <fullName>
     Rep. Neguse, Joe [D-CO-2]
    </fullName>
    <firstName>
     Joe
    </firstName>
    <lastName>
     Neguse
    </lastName>
    <party>
     D
    </party>
    <state>
     CO
    </state>
    <district>
     2
    </district>
    <sponsorshipDate>
     2021-03-23
    </sponsorshipDate>
    <isOriginalCosponsor>
     True
    </isOriginalCosponsor>
   </item>
   <item>
    <bioguideId>
     N000147
    </bioguideId>
    <fullName>
     Del. Norton, Eleanor Holmes [D-DC-At Large]
    </fullName>
    <firstName>
     ELEANOR
    </firstName>
    <lastName>
     NORTON
    </lastName>
    <party>
     D
    </party>
    <state>
     DC
    </state>
    <middleName>
     HOLMES
    </middleName>
    <district>
     0
    </district>
    <sponsorshipDate>
     2021-03-23
    </sponsorshipDate>
    <isOriginalCosponsor>
     True
    </isOriginalCosponsor>
   </item>
   <item>
    <bioguideId>
     O000172
    </bioguideId>
    <fullName>
     Rep. Ocasio-Cortez, Alexandria [D-NY-14]
    </fullName>
    <firstName>
     Alexandria
    </firstName>
    <lastName>
     Ocasio-Cortez
    </lastName>
    <party>
     D
    </party>
    <state>
     NY
    </state>
    <district>
     14
    </district>
    <sponsorshipDate>
     2021-03-23
    </sponsorshipDate>
    <isOriginalCosponsor>
     True
    </isOriginalCosponsor>
   </item>
   <item>
    <bioguideId>
     O000173
    </bioguideId>
    <fullName>
     Rep. Omar, Ilhan [D-MN-5]
    </fullName>
    <firstName>
     Ilhan
    </firstName>
    <lastName>
     Omar
    </lastName>
    <party>
     D
    </party>
    <state>
     MN
    </state>
    <district>
     5
    </district>
    <sponsorshipDate>
     2021-03-23
    </sponsorshipDate>
    <isOriginalCosponsor>
     True
    </isOriginalCosponsor>
   </item>
   <item>
    <bioguideId>
     P000607
    </bioguideId>
    <fullName>
     Rep. Pocan, Mark [D-WI-2]
    </fullName>
    <firstName>
     Mark
    </firstName>
    <lastName>
     Pocan
    </lastName>
    <party>
     D
    </party>
    <state>
     WI
    </state>
    <district>
     2
    </district>
    <sponsorshipDate>
     2021-03-23
    </sponsorshipDate>
    <isOriginalCosponsor>
     True
    </isOriginalCosponsor>
   </item>
   <item>
    <bioguideId>
     P000617
    </bioguideId>
    <fullName>
     Rep. Pressley, Ayanna [D-MA-7]
    </fullName>
    <firstName>
     Ayanna
    </firstName>
    <lastName>
     Pressley
    </lastName>
    <party>
     D
    </party>
    <state>
     MA
    </state>
    <district>
     7
    </district>
    <sponsorshipDate>
     2021-03-23
    </sponsorshipDate>
    <isOriginalCosponsor>
     True
    </isOriginalCosponsor>
   </item>
   <item>
    <bioguideId>
     R000606
    </bioguideId>
    <fullName>
     Rep. Raskin, Jamie [D-MD-8]
    </fullName>
    <firstName>
     Jamie
    </firstName>
    <lastName>
     Raskin
    </lastName>
    <party>
     D
    </party>
    <state>
     MD
    </state>
    <district>
     8
    </district>
    <sponsorshipDate>
     2021-03-23
    </sponsorshipDate>
    <isOriginalCosponsor>
     True
    </isOriginalCosponsor>
   </item>
   <item>
    <bioguideId>
     S001145
    </bioguideId>
    <fullName>
     Rep. Schakowsky, Janice D. [D-IL-9]
    </fullName>
    <firstName>
     JANICE
    </firstName>
    <lastName>
     SCHAKOWSKY
    </lastName>
    <party>
     D
    </party>
    <state>
     IL
    </state>
    <middleName>
     D.
    </middleName>
    <district>
     9
    </district>
    <sponsorshipDate>
     2021-03-23
    </sponsorshipDate>
    <isOriginalCosponsor>
     True
    </isOriginalCosponsor>
   </item>
   <item>
    <bioguideId>
     T000481
    </bioguideId>
    <fullName>
     Rep. Tlaib, Rashida [D-MI-13]
    </fullName>
    <firstName>
     Rashida
    </firstName>
    <lastName>
     Tlaib
    </lastName>
    <party>
     D
    </party>
    <state>
     MI
    </state>
    <district>
     13
    </district>
    <sponsorshipDate>
     2021-03-23
    </sponsorshipDate>
    <isOriginalCosponsor>
     True
    </isOriginalCosponsor>
   </item>
   <item>
    <bioguideId>
     W000800
    </bioguideId>
    <fullName>
     Rep. Welch, Peter [D-VT-At Large]
    </fullName>
    <firstName>
     Peter
    </firstName>
    <lastName>
     Welch
    </lastName>
    <party>
     D
    </party>
    <state>
     VT
    </state>
    <district>
     0
    </district>
    <sponsorshipDate>
     2021-03-23
    </sponsorshipDate>
    <isOriginalCosponsor>
     True
    </isOriginalCosponsor>
   </item>
   <item>
    <bioguideId>
     B001224
    </bioguideId>
    <fullName>
     Rep. Bush, Cori [D-MO-1]
    </fullName>
    <firstName>
     Cori
    </firstName>
    <lastName>
     Bush
    </lastName>
    <party>
     D
    </party>
    <state>
     MO
    </state>
    <district>
     1
    </district>
    <sponsorshipDate>
     2021-03-26
    </sponsorshipDate>
    <isOriginalCosponsor>
     False
    </isOriginalCosponsor>
   </item>
   <item>
    <bioguideId>
     D000623
    </bioguideId>
    <fullName>
     Rep. DeSaulnier, Mark [D-CA-11]
    </fullName>
    <firstName>
     Mark
    </firstName>
    <lastName>
     DeSaulnier
    </lastName>
    <party>
     D
    </party>
    <state>
     CA
    </state>
    <district>
     11
    </district>
    <sponsorshipDate>
     2021-03-26
    </sponsorshipDate>
    <isOriginalCosponsor>
     False
    </isOriginalCosponsor>
   </item>
  </cosponsors>
  <policyArea>
   <name>
    Health
   </name>
  </policyArea>
  <subjects>
   <legislativeSubjects>
    <item>
     <name>
      Administrative remedies
     </name>
    </item>
    <item>
     <name>
      Asia
     </name>
    </item>
    <item>
     <name>
      Business records
     </name>
    </item>
    <item>
     <name>
      Canada
     </name>
    </item>
    <item>
     <name>
      Civil actions and liability
     </name>
    </item>
    <item>
     <name>
      Competition and antitrust
     </name>
    </item>
    <item>
     <name>
      Department of Health and Human Services
     </name>
    </item>
    <item>
     <name>
      Drug safety, medical device, and laboratory regulation
     </name>
    </item>
    <item>
     <name>
      Europe
     </name>
    </item>
    <item>
     <name>
      France
     </name>
    </item>
    <item>
     <name>
      Germany
     </name>
    </item>
    <item>
     <name>
      Government information and archives
     </name>
    </item>
    <item>
     <name>
      Government studies and investigations
     </name>
    </item>
    <item>
     <name>
      Health care costs and insurance
     </name>
    </item>
    <item>
     <name>
      Health information and medical records
     </name>
    </item>
    <item>
     <name>
      Inflation and prices
     </name>
    </item>
    <item>
     <name>
      Intellectual property
     </name>
    </item>
    <item>
     <name>
      Japan
     </name>
    </item>
    <item>
     <name>
      Licensing and registrations
     </name>
    </item>
    <item>
     <name>
      Manufacturing
     </name>
    </item>
    <item>
     <name>
      Marketing and advertising
     </name>
    </item>
    <item>
     <name>
      Medical research
     </name>
    </item>
    <item>
     <name>
      Prescription drugs
     </name>
    </item>
    <item>
     <name>
      Research and development
     </name>
    </item>
    <item>
     <name>
      United Kingdom
     </name>
    </item>
   </legislativeSubjects>
   <policyArea>
    <name>
     Health
    </name>
   </policyArea>
  </subjects>
  <summaries>
   <summary>
    <versionCode>
     00
    </versionCode>
    <actionDate>
     2021-03-23
    </actionDate>
    <actionDesc>
     Introduced in House
    </actionDesc>
    <updateDate>
     2021-06-24T22:49:30Z
    </updateDate>
    <text>
     &lt;p&gt;&lt;b&gt;Prescription Drug Price Relief Act of 2021&lt;/b&gt;&lt;/p&gt; &lt;p&gt;This bill establishes a series of oversight and disclosure requirements relating to the prices of brand-name drugs. &lt;/p&gt; &lt;p&gt;Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all brand-name drugs for excessive pricing; HHS must also review prices upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug.&lt;/p&gt; &lt;p&gt;Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including development cost, revenue, and the size of the affected patient population. &lt;/p&gt; &lt;p&gt;The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures. &lt;/p&gt;
    </text>
   </summary>
  </summaries>
  <title>
   Prescription Drug Price Relief Act of 2021
  </title>
  <titles>
   <item>
    <titleType>
     Display Title
    </titleType>
    <title>
     Prescription Drug Price Relief Act of 2021
    </title>
   </item>
   <item>
    <titleType>
     Official Title as Introduced
    </titleType>
    <title>
     To significantly lower prescription drug prices for patients in the United States by ending government-granted monopolies for manufacturers who charge drug prices that are higher than the median prices at which the drugs are available in other countries.
    </title>
    <billTextVersionName>
     Introduced in House
    </billTextVersionName>
    <billTextVersionCode>
     IH
    </billTextVersionCode>
   </item>
   <item>
    <titleType>
     Short Title(s) as Introduced
    </titleType>
    <title>
     Prescription Drug Price Relief Act of 2021
    </title>
    <billTextVersionName>
     Introduced in House
    </billTextVersionName>
    <billTextVersionCode>
     IH
    </billTextVersionCode>
   </item>
  </titles>
  <textVersions>
   <item>
    <type>
     Introduced in House
    </type>
    <date>
     2021-03-23T04:00:00Z
    </date>
    <formats>
     <item>
      <url>
       https://www.govinfo.gov/content/pkg/BILLS-117hr2148ih/xml/BILLS-117hr2148ih.xml
      </url>
     </item>
    </formats>
   </item>
  </textVersions>
  <latestAction>
   <actionDate>
    2021-10-19
   </actionDate>
   <text>
    Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
   </text>
  </latestAction>
 </bill>
 <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
  <dc:format>
   text/xml
  </dc:format>
  <dc:language>
   EN
  </dc:language>
  <dc:rights>
   Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
  </dc:rights>
  <dc:contributor>
   Congressional Research Service, Library of Congress
  </dc:contributor>
  <dc:description>
   This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.
  </dc:description>
 </dublinCore>
</billStatus>

2021-10-19
Administrative State, Regulatory Reform, and Antitrust Subcommittee
hsju05
1
House committee actions
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Committee
2021-03-24
Health Subcommittee
hsif14
1
House committee actions
Referred to the Subcommittee on Health.
Committee
H11100
2021-03-23
Judiciary Committee
hsju00
2
House floor actions
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
IntroReferral
H11100
2021-03-23
Energy and Commerce Committee
hsif00
2
House floor actions
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
IntroReferral
Intro-H
2021-03-23
9
Library of Congress
Introduced in House
IntroReferral
1000
2021-03-23
9
Library of Congress
Introduced in House
IntroReferral
2021-03-23T15:02:45Z
Referred to
House
Judiciary Committee
2021-10-19T20:23:41Z
Referred to
Administrative State, Regulatory Reform, and Antitrust Subcommittee
hsju05
hsju00
Standing
2021-03-23T15:02:40Z
Referred to
House
Energy and Commerce Committee
2021-03-24T15:23:15Z
Referred to
Health Subcommittee
hsif14
hsif00
Standing
B001223
16
Jamaal
Rep. Bowman, Jamaal [D-NY-16]
Bowman
D
2021-03-23
NY
D000191
4
PETER
Rep. DeFazio, Peter A. [D-OR-4]
DEFAZIO
A.
D
2021-03-23
OR
D000216
3
ROSA
Rep. DeLauro, Rosa L. [D-CT-3]
DELAURO
D
2021-03-23
CT
J000298
7
Pramila
Rep. Jayapal, Pramila [D-WA-7]
Jayapal
D
2021-03-23
WA
J000306
17
Mondaire
Rep. Jones, Mondaire [D-NY-17]
Jones
D
2021-03-23
NY
L000551
13
BARBARA
Rep. Lee, Barbara [D-CA-13]
LEE
D
2021-03-23
CA
N000191
2
Joe
Rep. Neguse, Joe [D-CO-2]
Neguse
D
2021-03-23
CO
N000147
0
ELEANOR
Del. Norton, Eleanor Holmes [D-DC-At Large]
NORTON
HOLMES
D
2021-03-23
DC
O000172
14
Alexandria
Rep. Ocasio-Cortez, Alexandria [D-NY-14]
Ocasio-Cortez
D
2021-03-23
NY
O000173
5
Ilhan
Rep. Omar, Ilhan [D-MN-5]
Omar
D
2021-03-23
MN
P000607
2
Mark
Rep. Pocan, Mark [D-WI-2]
Pocan
D
2021-03-23
WI
P000617
7
Ayanna
Rep. Pressley, Ayanna [D-MA-7]
Pressley
D
2021-03-23
MA
R000606
8
Jamie
Rep. Raskin, Jamie [D-MD-8]
Raskin
D
2021-03-23
MD
S001145
9
JANICE
Rep. Schakowsky, Janice D. [D-IL-9]
SCHAKOWSKY
D.
D
2021-03-23
IL
T000481
13
Rashida
Rep. Tlaib, Rashida [D-MI-13]
Tlaib
D
2021-03-23
MI
W000800
0
Peter
Rep. Welch, Peter [D-VT-At Large]
Welch
D
2021-03-23
VT
B001224
1
Cori
Rep. Bush, Cori [D-MO-1]
Bush
D
2021-03-26
MO
D000623
11
Mark
Rep. DeSaulnier, Mark [D-CA-11]
DeSaulnier
D
2021-03-26
CA
Congressional Research Service, Library of Congress
This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.
text/xml
EN
Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.
2021-03-23
2021-10-19
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
House
Health
2021-03-23
Committee on Health, Education, Labor, and Pensions Subcommittee on Primary Health and Retirement Security. Hearings held.
CRS
Identical bill
Prescription Drug Price Relief Act of 2021
S
K000389
17
Ro
Rep. Khanna, Ro [D-CA-17]
N
Khanna
D
CA
Administrative remedies Asia Business records Canada Civil actions and liability Competition and antitrust Department of Health and Human Services Drug safety, medical device, and laboratory regulation Europe France Germany Government information and archives Government studies and investigations Health care costs and insurance Health information and medical records Inflation and prices Intellectual property Japan Licensing and registrations Manufacturing Marketing and advertising Medical research Prescription drugs Research and development United Kingdom
2021-03-23
Introduced in House
 <p><b>Prescription Drug Price Relief Act of 2021</b></p> <p>This bill establishes a series of oversight and disclosure requirements relating to the prices of brand-name drugs. </p> <p>Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all brand-name drugs for excessive pricing; HHS must also review prices upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug.</p> <p>Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including development cost, revenue, and the size of the affected patient population. </p> <p>The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures. </p>
2021-06-24T22:49:30Z
00
2021-03-23T04:00:00Z
Introduced in House
https://www.govinfo.gov/content/pkg/BILLS-117hr2148ih/xml/BILLS-117hr2148ih.xml
Prescription Drug Price Relief Act of 2021
Prescription Drug Price Relief Act of 2021
Display Title
IH
Introduced in House
To significantly lower prescription drug prices for patients in the United States by ending government-granted monopolies for manufacturers who charge drug prices that are higher than the median prices at which the drugs are available in other countries.
Official Title as Introduced
IH
Introduced in House
Prescription Drug Price Relief Act of 2021
Short Title(s) as Introduced
HR
2023-01-11T13:48:04Z
2023-01-11T13:48:04Z
3.0.0
2021-03-23
Committee on Health, Education, Labor, and Pensions Subcommittee on Primary Health and Retirement Security. Hearings held.
CRS
Identical bill
Prescription Drug Price Relief Act of 2021
S
2021-10-19
Administrative State, Regulatory Reform, and Antitrust Subcommittee
hsju05
1
House committee actions
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.
Committee
2021-03-24
Health Subcommittee
hsif14
1
House committee actions
Referred to the Subcommittee on Health.
Committee
H11100
2021-03-23
Judiciary Committee
hsju00
2
House floor actions
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
IntroReferral
H11100
2021-03-23
Energy and Commerce Committee
hsif00
2
House floor actions
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
IntroReferral
Intro-H
2021-03-23
9
Library of Congress
Introduced in House
IntroReferral
1000
2021-03-23
9
Library of Congress
Introduced in House
IntroReferral
K000389
17
Ro
Rep. Khanna, Ro [D-CA-17]
N
Khanna
D
CA
B001223
16
Jamaal
Rep. Bowman, Jamaal [D-NY-16]
Bowman
D
2021-03-23
NY
D000191
4
PETER
Rep. DeFazio, Peter A. [D-OR-4]
DEFAZIO
A.
D
2021-03-23
OR
D000216
3
ROSA
Rep. DeLauro, Rosa L. [D-CT-3]
DELAURO
D
2021-03-23
CT
J000298
7
Pramila
Rep. Jayapal, Pramila [D-WA-7]
Jayapal
D
2021-03-23
WA
J000306
17
Mondaire
Rep. Jones, Mondaire [D-NY-17]
Jones
D
2021-03-23
NY
L000551
13
BARBARA
Rep. Lee, Barbara [D-CA-13]
LEE
D
2021-03-23
CA
N000191
2
Joe
Rep. Neguse, Joe [D-CO-2]
Neguse
D
2021-03-23
CO
N000147
0
ELEANOR
Del. Norton, Eleanor Holmes [D-DC-At Large]
NORTON
HOLMES
D
2021-03-23
DC
O000172
14
Alexandria
Rep. Ocasio-Cortez, Alexandria [D-NY-14]
Ocasio-Cortez
D
2021-03-23
NY
O000173
5
Ilhan
Rep. Omar, Ilhan [D-MN-5]
Omar
D
2021-03-23
MN
P000607
2
Mark
Rep. Pocan, Mark [D-WI-2]
Pocan
D
2021-03-23
WI
P000617
7
Ayanna
Rep. Pressley, Ayanna [D-MA-7]
Pressley
D
2021-03-23
MA
R000606
8
Jamie
Rep. Raskin, Jamie [D-MD-8]
Raskin
D
2021-03-23
MD
S001145
9
JANICE
Rep. Schakowsky, Janice D. [D-IL-9]
SCHAKOWSKY
D.
D
2021-03-23
IL
T000481
13
Rashida
Rep. Tlaib, Rashida [D-MI-13]
Tlaib
D
2021-03-23
MI
W000800
0
Peter
Rep. Welch, Peter [D-VT-At Large]
Welch
D
2021-03-23
VT
B001224
1
Cori
Rep. Bush, Cori [D-MO-1]
Bush
D
2021-03-26
MO
D000623
11
Mark
Rep. DeSaulnier, Mark [D-CA-11]
DeSaulnier
D
2021-03-26
CA
Administrative remedies Asia Business records Canada Civil actions and liability Competition and antitrust Department of Health and Human Services Drug safety, medical device, and laboratory regulation Europe France Germany Government information and archives Government studies and investigations Health care costs and insurance Health information and medical records Inflation and prices Intellectual property Japan Licensing and registrations Manufacturing Marketing and advertising Medical research Prescription drugs Research and development United Kingdom
2021-03-23
Introduced in House
 <p><b>Prescription Drug Price Relief Act of 2021</b></p> <p>This bill establishes a series of oversight and disclosure requirements relating to the prices of brand-name drugs. </p> <p>Specifically, the bill requires the Department of Health and Human Services (HHS) to review at least annually all brand-name drugs for excessive pricing; HHS must also review prices upon petition. If any such drugs are found to be excessively priced, HHS must (1) void any government-granted exclusivity; (2) issue open, nonexclusive licenses for the drugs; and (3) expedite the review of corresponding applications for generic drugs and biosimilar biological products. HHS must also create a public database with its determinations for each drug.</p> <p>Under the bill, a price is considered excessive if the domestic average manufacturing price exceeds the median price for the drug in Canada, the United Kingdom, Germany, France, and Japan. If a price does not meet this criteria, or if pricing information is unavailable in at least three of the aforementioned countries, the price is still considered excessive if it is higher than reasonable in light of specified factors, including development cost, revenue, and the size of the affected patient population. </p> <p>The bill also requires drug manufacturers to report specified financial information for brand-name drugs, including research and advertising expenditures. </p>
2021-06-24T22:49:30Z
00
Prescription Drug Price Relief Act of 2021
Prescription Drug Price Relief Act of 2021
Display Title
IH
Introduced in House
To significantly lower prescription drug prices for patients in the United States by ending government-granted monopolies for manufacturers who charge drug prices that are higher than the median prices at which the drugs are available in other countries.
Official Title as Introduced
IH
Introduced in House
Prescription Drug Price Relief Act of 2021
Short Title(s) as Introduced
2021-10-19
Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.